Dievini Hopp Biotech Holding (dievini) is a German investment company that focuses on early-stage life science companies.
The company was founded in 2007 by Dietmar Hopp, the co-founder of SAP. dievini is headquartered in Walldorf, Germany, and has offices in London, Paris, and Boston.
Dievini’s investment strategy is focused on companies that are developing innovative new drugs, therapies, and diagnostics.
Top German PE Firms
Paragon Partners
Paragon Partners is a private equity firm headquartered in Munich, Germany, that invests in medium-sized companies in the German-speaking region. The firm was founded in 2004 and has over €2.4 billion in assets under management. Paragon Partners’ investment strategy is…
DWS Group: One of the World’s Leading Asset Managers
DWS Group (Deutsche Asset Management) is one of the world’s leading asset managers, with over €840 billion in assets under management. The company was founded in 1956 and is headquartered…
KFW DEG: One of the World’s Leading Development Finance Institutions
KfW DEG (German Development Finance Corporation) is a subsidiary of the KfW Group and one of the world’s leading development finance institutions (DFIs). It is specialized in providing long-term capital,…
Deutsche Beteiligungs: A Closed End Fund Based in Frankfurt
Deutsche Beteiligungs AG (DBAG) is a listed German investment company headquartered in Frankfurt am Main. It originates closed-end private equity funds and invests in well-positioned mid-market companies with potential. DBAG…
COI Partners: Investing in High Growth Companies in the German Speaking Region
COI Partners is a private equity firm headquartered in Zurich, Switzerland, that invests in high-growth small and medium-sized companies in the German-speaking region. The firm was founded in 2001 and…
The company invests in a variety of therapeutic areas, including cancer, immunology, infectious diseases, and neuroscience.
Dievini has a strong track record of success. Some of the company’s most notable investments include:
- BioNTech (mRNA vaccines)
- CureVac (mRNA vaccines)
- Heidelberg Pharma (immunotherapies)
- InflaRx (antibody therapies)
- Morphosys (antibody therapies)
- Translate Bio (mRNA therapeutics)
Dievini is an important investor in the German biotech sector and plays a key role in supporting the development of innovative new drugs and therapies. The company is committed to helping its portfolio companies achieve their full potential and bring their products to market.
Here are some of the key benefits of working with dievini:
- Access to capital: dievini has a large pool of capital to invest in early-stage life science companies. The company offers a variety of financing solutions, including equity, mezzanine capital, and debt.
- Expertise and resources: dievini has a team of experienced investment professionals with a deep understanding of the life science sector. The company is also able to provide its portfolio companies with a wide range of support services, including strategic advice, operational expertise, and access to a network of contacts.
- Track record of success: dievini has a strong track record of success in investing in early-stage life science companies and helping them to achieve their full potential.
